WAYNE, Pa. and MISGAV, Israel, March 5, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump™, a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present a corporate overview at the 26th Annual ROTH Capital Growth Conference in Laguna Niguel on Tuesday, March 11, 2014 at 8:00am PDT.
Help employers find you! Check out all the jobs and post your resume.
